UA114705C2 - Андрогенна композиція для лікування офтальмологічного захворювання - Google Patents

Андрогенна композиція для лікування офтальмологічного захворювання

Info

Publication number
UA114705C2
UA114705C2 UAA201310270A UAA201310270A UA114705C2 UA 114705 C2 UA114705 C2 UA 114705C2 UA A201310270 A UAA201310270 A UA A201310270A UA A201310270 A UAA201310270 A UA A201310270A UA 114705 C2 UA114705 C2 UA 114705C2
Authority
UA
Ukraine
Prior art keywords
treating
composition
androgen
androgen composition
opthalmic
Prior art date
Application number
UAA201310270A
Other languages
English (en)
Inventor
Джон Т. ТРОГДЕН
Аднан К. САЛАМЕХ
Четан П. ПУДЖАРА
Анурадха В. ГОР
Джая Гіянані
Original Assignee
Аллерган, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45567134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA114705(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Аллерган, Інк. filed Critical Аллерган, Інк.
Publication of UA114705C2 publication Critical patent/UA114705C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Винахід стосується офтальмологічної композиції для лікування блефариту, яка містить фізіологічно ефективну кількість андрогену, що є тестостероном, і касторову олію, при цьому вказана композиція придатна для місцевого застосування в області верхньої і/або нижньої повіки.
UAA201310270A 2011-01-26 2012-01-25 Андрогенна композиція для лікування офтальмологічного захворювання UA114705C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161436274P 2011-01-26 2011-01-26
PCT/US2012/022508 WO2012103186A2 (en) 2011-01-26 2012-01-25 Androgen composition for treating an opthalmic condition

Publications (1)

Publication Number Publication Date
UA114705C2 true UA114705C2 (uk) 2017-07-25

Family

ID=45567134

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201310270A UA114705C2 (uk) 2011-01-26 2012-01-25 Андрогенна композиція для лікування офтальмологічного захворювання

Country Status (25)

Country Link
US (8) US9119772B2 (uk)
EP (2) EP2667877B1 (uk)
JP (1) JP6008876B2 (uk)
KR (1) KR101914940B1 (uk)
CN (2) CN103415292A (uk)
AR (1) AR084932A1 (uk)
AU (4) AU2012209184B2 (uk)
BR (1) BR112013019257B1 (uk)
CA (1) CA2825396C (uk)
CL (1) CL2013002134A1 (uk)
DK (1) DK2667877T3 (uk)
ES (1) ES2672238T3 (uk)
HU (1) HUE037660T2 (uk)
IL (1) IL227573A (uk)
MX (1) MX344046B (uk)
MY (1) MY175318A (uk)
NO (1) NO2667877T3 (uk)
PL (1) PL2667877T3 (uk)
RU (1) RU2599036C2 (uk)
SG (1) SG192114A1 (uk)
TR (1) TR201807857T4 (uk)
TW (1) TWI593412B (uk)
UA (1) UA114705C2 (uk)
WO (1) WO2012103186A2 (uk)
ZA (1) ZA201305812B (uk)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
RU2599036C2 (ru) 2011-01-26 2016-10-10 Аллерган, Инк. Андрогенная композиция для лечения офтальмологического заболевания
EP2855508B1 (en) 2012-06-01 2018-02-14 Allergan, Inc. Cyclosporin a analogs
US20140274985A1 (en) 2013-03-15 2014-09-18 Raman Malhotra Systemic administration of androgen in treating dry eye syndrome
RU2592370C9 (ru) * 2014-04-24 2016-08-27 Иван Иванович Дедов Средство на основе дегидроэпиандростерона, способ его применения
TWI516281B (zh) * 2014-07-16 2016-01-11 健維生技有限公司 改良之睪固酮製劑製法及所得之睪固酮製劑
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
US9914755B2 (en) 2015-01-08 2018-03-13 Allergan, Inc. Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized
MA42844A (fr) 2015-09-17 2018-07-25 Immunogen Inc Combinaisons thérapeutiques comprenant des immunoconjugués anti-folr1
EP3313413A4 (en) 2015-09-28 2018-07-11 Azura Opthalmics Ltd. Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
WO2017066429A1 (en) 2015-10-14 2017-04-20 Paul Gavaris Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents
BR112018070852B1 (pt) 2016-04-14 2024-01-16 Azura Ophthalmics Ltd Composições de dissulfeto de selênio
CA3091413A1 (en) * 2017-02-17 2018-08-23 Cempra Pharmaceuticals, Inc. Triazole-containing macrolides and ophthalmic uses therefor
WO2019209955A2 (en) * 2018-04-24 2019-10-31 Allergan, Inc. Presbyopia treatments
WO2020069450A1 (en) * 2018-09-28 2020-04-02 Joel Studin Transpore delivery of drugs and uses thereof
US10744153B1 (en) 2019-07-01 2020-08-18 Cloudbreak Therapeutics Llc Compositions and methods for treating meibomian gland dysfunction
CA3166357A1 (en) 2020-01-10 2021-07-15 Azura Ophthalmics Ltd. Instructions for composition and sensitivity
CA3209718A1 (en) * 2021-02-25 2022-09-01 Gary Michael PEKOE Composition for treatment of topical dermatological bacterial skin conditions
US11746253B2 (en) * 2021-03-08 2023-09-05 Hoi Ming Michael HO Sprayable conductive agent capable of forming conductive portion and manufacturing method and use thereof
US11951123B2 (en) * 2022-01-12 2024-04-09 Platform Ophthalmic Innovations, LLC Fortified nutritional lubricating drops for dry eye disease
CN115105512A (zh) * 2022-08-29 2022-09-27 中山大学中山眼科中心 脱氢表雄酮在制备预防、治疗眼部近视的药物中的用途及其剂型和制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2262182A (en) * 1939-05-23 1941-11-11 John V Huskamp Closure valve for containers
US3049003A (en) 1956-09-05 1962-08-14 Clark Equipment Co Torque measurement apparatus
DE3514724A1 (de) * 1985-04-24 1986-10-30 Albin F. Dr. 4200 Oberhausen Jereb Salbe zur verbeugung und behandlung von augen- und hauterkrankungen
US5364632A (en) 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US6093706A (en) * 1992-03-04 2000-07-25 Bioresponse, L.L.C. Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders
ATE185697T1 (de) 1992-04-21 1999-11-15 Schepens Eye Res Inst Androgentherapie am auge beim sjögrensyndrom
US6107289A (en) * 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
US5688765A (en) * 1992-04-21 1997-11-18 The Schepens Eye Research Institute, Inc. Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β
US5958912A (en) * 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
AU6401294A (en) 1993-03-12 1994-09-26 Allergan, Inc. Eye care products containing a pheromone additive and method of using the same
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
EP0878197B1 (en) 1997-05-14 2002-08-21 Senju Pharmaceutical Co., Ltd. Compositions containing difluprednate
ATE265847T1 (de) * 1997-07-29 2004-05-15 Upjohn Co Selbstemulgierbare formulierung enthaltend lipophile verbindungen
US5981607A (en) * 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
WO2000059512A1 (en) * 1999-04-01 2000-10-12 Akzo Nobel N.V. Formulation comprising testosteron undecanoate and castor oil
WO2001034549A1 (en) * 1999-11-09 2001-05-17 Alcon Universal Ltd. Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders
US20020009507A1 (en) * 2000-01-19 2002-01-24 Alcon Universal Ltd. Use of polyethoxylated castor oil for the treatment of dry eye
US20040214797A1 (en) * 2001-05-07 2004-10-28 Allergan, Inc. Preserved pharmaceutical compositions comprising cyclodextrins
US6872705B2 (en) * 2001-07-13 2005-03-29 Allergan, Inc. Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions
WO2003030894A1 (en) 2001-10-11 2003-04-17 Alcon, Inc. Methods for treating dry eye
US6659985B2 (en) * 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
US6983600B1 (en) * 2004-06-30 2006-01-10 General Electric Company Multi-venturi tube fuel injector for gas turbine combustors
DE602004017477D1 (de) 2004-11-09 2008-12-11 Novagali Pharma Sa Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential
AU2006218653A1 (en) * 2005-03-02 2006-09-08 Barnett, Gene Ph.D. Pharmaceutically acceptable carrier for ophthalmic compositions
US20090041783A1 (en) 2005-04-28 2009-02-12 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
US8697152B2 (en) * 2005-08-31 2014-04-15 Johnson & Johnson Consumer Companies, Inc. Anti-inflammatory compositions and personal care compositions comprising olive leaf (Olea europea) extract
EP2583668B1 (en) 2005-10-26 2014-10-08 CyDex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US20070287983A1 (en) * 2006-06-07 2007-12-13 Richard Worthington Lodge Absorbent article having an anchored core assembly
US7390302B2 (en) 2006-08-16 2008-06-24 The General Electric Company Method and system of determining NIBP target inflation pressure using an SpO2 plethysmograph signal
US20080045486A1 (en) * 2006-08-17 2008-02-21 Tang-Liu Diane D S Ocular administration of testosterone
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US20100305046A1 (en) * 2009-06-02 2010-12-02 Abbott Medical Optics Inc. Stable cyclosporine containing ophthalmic emulsion for treating dry eyes
RU2599036C2 (ru) 2011-01-26 2016-10-10 Аллерган, Инк. Андрогенная композиция для лечения офтальмологического заболевания

Also Published As

Publication number Publication date
JP2014503588A (ja) 2014-02-13
MX344046B (es) 2016-12-02
AU2020267198A1 (en) 2020-12-10
KR101914940B1 (ko) 2018-11-06
JP6008876B2 (ja) 2016-10-19
TWI593412B (zh) 2017-08-01
US9119772B2 (en) 2015-09-01
US20210268002A1 (en) 2021-09-02
US10905696B2 (en) 2021-02-02
AU2017228623A1 (en) 2017-10-05
ES2672238T3 (es) 2018-06-13
WO2012103186A3 (en) 2012-09-20
US20220202829A1 (en) 2022-06-30
HUE037660T2 (hu) 2018-09-28
KR20140045327A (ko) 2014-04-16
BR112013019257B1 (pt) 2019-09-03
MX2013008528A (es) 2013-08-29
CA2825396A1 (en) 2012-08-02
AU2019202511A1 (en) 2019-05-02
US20180221388A1 (en) 2018-08-09
US20170189412A1 (en) 2017-07-06
IL227573A (en) 2017-04-30
MY175318A (en) 2020-06-19
US20140315872A1 (en) 2014-10-23
AU2012209184B2 (en) 2017-06-15
EP2667877B1 (en) 2018-03-07
US20210113588A1 (en) 2021-04-22
CN103415292A (zh) 2013-11-27
US20120190661A1 (en) 2012-07-26
PL2667877T3 (pl) 2018-09-28
EP3388066B1 (en) 2020-11-04
EP3388066A1 (en) 2018-10-17
ZA201305812B (en) 2014-04-30
EP2667877A2 (en) 2013-12-04
RU2599036C2 (ru) 2016-10-10
CN109700763A (zh) 2019-05-03
AR084932A1 (es) 2013-07-10
US20150366800A1 (en) 2015-12-24
US10780098B2 (en) 2020-09-22
CA2825396C (en) 2016-09-06
DK2667877T3 (en) 2018-06-14
BR112013019257A2 (pt) 2016-10-11
IL227573A0 (en) 2013-09-30
WO2012103186A2 (en) 2012-08-02
NZ613699A (en) 2015-09-25
RU2013138256A (ru) 2015-03-10
TW201309302A (zh) 2013-03-01
TR201807857T4 (tr) 2018-06-21
NO2667877T3 (uk) 2018-08-04
US9504646B2 (en) 2016-11-29
US9937188B2 (en) 2018-04-10
SG192114A1 (en) 2013-08-30
CL2013002134A1 (es) 2013-11-29

Similar Documents

Publication Publication Date Title
UA114705C2 (uk) Андрогенна композиція для лікування офтальмологічного захворювання
MX2015001250A (es) Composiciones y tratamiento para enfermedades y trastornos del ojo.
CO7000769A2 (es) Composiciones y métodos para el tratamiento de presbicia, hipermetropía leve, y astigmatismo irregular
MX2011013061A (es) Formulaciones oftalmicas de fluticasona y metodos de uso.
MY171920A (en) Prevention and treatment of ocular conditions
NZ727304A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
MX2014015004A (es) Inhibidores de bromodominio de benzo [c] isoxazoloazepina y sus usos.
EA201500362A1 (ru) Ингибиторы rho-киназы
MY169328A (en) Compositions for the treatment of dry eye
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
EP2624916A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE OBESE, NEOVASCULARIZATION AND RELATED DISEASES
IL227412A (en) Administration of cross-materials to corne by iontophoresis for the treatment of keratoconus and ophthalmic preparations for this purpose
FI20115135L (fi) Mikrofibrilloitu selluloosa käytettäväksi erityisesti atooppisen ihotulehduksen ja psoriasiksen hoidossa
MX2015003701A (es) Composiciones para tratamiento.
EP3086809A4 (en) Compositions and methods of treating ocular diseases
WO2011116020A3 (en) Ophthalmic formulations of cetirizine and methods of use
MX367393B (es) Composiciones antifungicas para el tratamiento de piel y uñas.
IN2014KN02914A (uk)
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
BR112015004469A2 (pt) sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares
HK1210417A1 (en) Compositions, methods and/or devices for prevention and/or treatment of dry eye disorders //
EA201500778A1 (ru) Композиция по уходу за кожей
IN2015KN00370A (uk)
EP2910247A4 (en) COMPOSITIONS FOR PREVENTING OR TREATING ALLERGIC SKIN DISORDERS CONTAINING GPCR19 AGENTS AS ACTIVE INGREDIENTS
MX2013015419A (es) Dha y epa en la reduccion de estres oxidante.